Skip to content
Titration

The semaglutide titration schedule, explained

Why semaglutide starts low and steps up — and how to keep track of which week and dose you're on, privately.

Lirea Team

Semaglutide isn’t a take-and-stay medication — it climbs. Whether you have it as Ozempic, Wegovy, or a compounded version, you start low and step up over several months. Here’s why, and how to keep the schedule straight.

Why the slow climb

Starting at a low dose and increasing gradually gives your body time to adjust, which is what keeps early side effects manageable. The first dose is deliberately sub-therapeutic — it’s a ramp, not the destination. That’s why “how much weight have I lost?” in week two is the wrong question.

What a typical schedule looks like

The standard clinical schedule moves up in steps every few weeks. Wegovy, for weight management, climbs to a higher maintenance dose than Ozempic typically does. Your prescriber sets your actual pace — and may hold you at a level longer if side effects need it.

We don’t print dose numbers as guidance here; the point is the shape: low start, step-ups, a maintenance dose you settle at. Your own schedule is the one that matters.

“What week am I on?”

This is the question that gets lost. Once you’ve stepped up a couple of times, the weeks blur. Knowing your current dose and how long you’ve been on it tells you whether it’s time to expect a step-up — and gives your prescriber an accurate picture.

A tracker that shows your current step, with the option to hold or step back, turns a fuzzy memory into a clear answer.

Keep your schedule yours

Your titration history is personal. With Lirea it stays on your device — encrypted, no account, no server.

Low start, gradual steps, a dose you settle at — and a clear record of where you are.

Track the step, not just the shot, and the climb stays legible the whole way up.


Your shot. Your data. Your device.

Start privately

Your shot. Your data. Your device.

Track your weekly dose, your titration, and how you’re feeling — all on your device. No account required.

Coming soon to iOS and Android.